Edition:
United States

Menlo Therapeutics Inc (MNLO.OQ)

MNLO.OQ on NASDAQ Stock Exchange Global Select Market

6.51USD
16 Oct 2018
Change (% chg)

$0.12 (+1.88%)
Prev Close
$6.39
Open
$6.42
Day's High
$6.60
Day's Low
$6.24
Volume
21,215
Avg. Vol
46,841
52-wk High
$38.68
52-wk Low
$5.63

Latest Key Developments (Source: Significant Developments)

Menlo Therapeutics Announces Results From A Phase 2 Clinical Trial Of Serlopitant For Treatment Of Refractory Chronic Cough
Monday, 8 Oct 2018 08:00am EDT 

Oct 8 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS ANNOUNCES RESULTS FROM A PHASE 2 CLINICAL TRIAL OF SERLOPITANT FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH.MENLO THERAPEUTICS INC - SERLOPITANT FAILS TO DEMONSTRATE EFFICACY RELATIVE TO PLACEBO ON PRIMARY AND SECONDARY ENDPOINTS.MENLO THERAPEUTICS INC - SERLOPITANT WAS WELL-TOLERATED IN STUDY.MENLO THERAPEUTICS INC - TREATMENT RELATED ADVERSE EVENTS OCCURRED AT COMPARABLE RATES IN SERLOPITANT AND PLACEBO TREATED GROUPS.MENLO THERAPEUTICS - PHASE 2 CLINICAL TRIAL OF SERLOPITANT TO TREAT PRURITUS ASSOCIATED WITH PSORIASIS IS FULLY ENROLLED, DATA EXPECTED IN DEC 2018.MENLO THERAPEUTICS - CURRENTLY ENROLLING PATIENTS IN 2 PHASE 3 TRIALS TO EVALUATE SERLOPITANT AS TREATMENT FOR PRURITUS ASSOCIATED WITH PRURIGO NODULARIS.MENLO THERAPEUTICS - DATA FROM 2 TRIALS TO EVALUATE SERLOPITANT AS TREATMENT FOR PRURITUS ASSOCIATED WITH PRURIGO NODULARIS EXPECTED IN FIRST HALF OF 2020.MENLO THERAPEUTICS - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL IN PATIENTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN IN 2018, EXPECT RESULTS IN FIRST HALF OF 2020.  Full Article

Menlo Therapeutics Q2 Loss Per Share $0.36
Wednesday, 1 Aug 2018 04:05pm EDT 

Aug 1 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.36.Q2 EARNINGS PER SHARE VIEW $-0.79 -- THOMSON REUTERS I/B/E/S.  Full Article

Menlo Therapeutics Reports Qtrly Loss Per Share $0.72
Wednesday, 9 May 2018 04:05pm EDT 

May 9 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.72.LOWERING ITS OPERATING EXPENSE GUIDANCE FOR FULL YEAR 2018 TO A RANGE OF APPROXIMATELY $68.0 MILLION TO $78.0 MILLION.  Full Article

Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant Halted
Tuesday, 24 Apr 2018 04:31pm EDT 

April 24 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS - CO'S PARTNERS FOR COMMERCIALIZATION OF SERLOPITANT IN JAPAN, INFORMED DECISION TO HALT JAPANESE PHASE 2 CLINICAL TRIAL OF SERLOPITANT.MENLO SAYS JT TORII HAS INDICATED THEY ARE REEVALUATING THEIR SERLOPITANT DEVELOPMENT PROGRAM BASED UPON EVOLVING COMMERCIAL CONSIDERATIONS IN JAPAN.MENLO THERAPEUTICS INC - BASED UPON COMMUNICATION WITH JT TORII, CO EXPECTS JT TORII LICENSE AGREEMENT FOR SERLOPITANT WILL ULTIMATELY BE TERMINATED.  Full Article

Menlo Therapeutics Prices IPO Of 7 Mln Shares At $17/Share
Wednesday, 24 Jan 2018 08:47pm EST 

Jan 24 (Reuters) - Menlo Therapeutics Inc ::ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF COMMON STOCK.SAYS INITIAL PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.  Full Article

Menlo Therapeutics Now Sees IPO Of 6.5 Mln Shares Of Common Stock Priced Between $16 And $17 Per Share
Tuesday, 23 Jan 2018 06:58am EST 

Jan 23 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS INC NOW SEES IPO OF 6.5 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $16.00 AND $17.00 PER SHARE - SEC FILING.MENLO THERAPEUTICS INC SAYS IT HAD PREVIOUSLY EXPECTED IPO OF 5.67 MILLION SHARES OF COMMON STOCK PRICED BETWEE $14.00 AND $16.00 PER SHARE.  Full Article